Differential accumulation of storage bodies with aging defines discrete subsets of microglia in the healthy brain

  1. Jeremy Carlos Burns
  2. Bunny Cotleur
  3. Dirk M Walther
  4. Bekim Bajrami
  5. Stephen J Rubino
  6. Ru Wei
  7. Nathalie Franchimont
  8. Susan L Cotman
  9. Richard M Ransohoff
  10. Michael Mingueneau  Is a corresponding author
  1. Biogen, United States
  2. Harvard Medical School, United States
  3. Third Rock Ventures, United States

Abstract

To date, microglia subsets in the healthy CNS have not been identified. Utilizing autofluorescence (AF) as a discriminating parameter, we identified two novel microglia subsets in both mice and non-human primates, termed autofluorescence-positive (AF+) and negative (AF-). While their proportion remained constant throughout most adult life, the AF signal linearly and specifically increased in AF+ microglia with age and correlated with a commensurate increase in size and complexity of lysosomal storage bodies, as detected by transmission electron microscopy and LAMP1 levels. Post-depletion repopulation kinetics revealed AF- cells as likely precursors of AF+ microglia. At the molecular level, the proteome of AF+ microglia showed overrepresentation of endolysosomal, autophagic, catabolic, and mTOR-related proteins. Mimicking the effect of advanced aging, genetic disruption of lysosomal function accelerated the accumulation of storage bodies in AF+ cells and led to impaired microglia physiology and cell death, suggestive of a mechanistic convergence between aging and lysosomal storage disorders.

Data availability

Data are available via ProteomeXchange with identifier PXD017505.Submission details: Project Name: Autofluorescence positive and negative microglia constitute novel subsets found in healthy brain. Project accession: PXD017505

The following data sets were generated

Article and author information

Author details

  1. Jeremy Carlos Burns

    Multiple Sclerosis Research Unit, Biogen, Cambridge, United States
    Competing interests
    Jeremy Carlos Burns, currently a full-time employee of Biogen.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3853-0237
  2. Bunny Cotleur

    Emerging Neurosciences Research Unit, Biogen, Cambridge, United States
    Competing interests
    Bunny Cotleur, currently a full-time employee of Biogen.
  3. Dirk M Walther

    Chemical Biology and Proteomics, Biogen, Cambridge, United States
    Competing interests
    Dirk M Walther, currently a full-time employee of Biogen.
  4. Bekim Bajrami

    Chemical Biology and Proteomics, Biogen, Cambridge, United States
    Competing interests
    Bekim Bajrami, currently a full-time employee of Biogen.
  5. Stephen J Rubino

    Multiple Sclerosis Research Unit, Biogen, Cambridge, United States
    Competing interests
    Stephen J Rubino, currently a full-time employee of Biogen.
  6. Ru Wei

    Chemical Biology and Proteomics, Biogen, Cambridge, United States
    Competing interests
    Ru Wei, currently a full-time employee of Biogen.
  7. Nathalie Franchimont

    Multiple Sclerosis Research Unit, Biogen, Cambridge, United States
    Competing interests
    Nathalie Franchimont, currently a full-time employee of Biogen.
  8. Susan L Cotman

    Center for Genomic Medicine, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  9. Richard M Ransohoff

    Third Rock Ventures, Boston, United States
    Competing interests
    Richard M Ransohoff, currently a full-time employee of Third Rock Ventures.
  10. Michael Mingueneau

    Immunology Research, Biogen, Cambridge, United States
    For correspondence
    michael.mingueneau@biogen.com
    Competing interests
    Michael Mingueneau, currently a full-time employee of Biogen.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3873-7329

Funding

Batten Disease Support and Research Association

  • Susan L Cotman

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Suzanne R Pfeffer, Stanford University School of Medicine, United States

Ethics

Animal experimentation: This study was performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Research animals at Biogen were housed in an AAALAC accredited facility and handled according to an approved institutional animal care and use committee (IACUC) protocol (#756). This study was reviewed and approved by the Massachusetts General Hospital (MGH) Subcommittee of Research Animal Care (SRAC), which serves as the Institutional Animal Care and Use Committee (IACUC) for MGH (Protocol #2008N000013).

Version history

  1. Received: April 21, 2020
  2. Accepted: June 21, 2020
  3. Accepted Manuscript published: June 24, 2020 (version 1)
  4. Version of Record published: July 17, 2020 (version 2)

Copyright

© 2020, Burns et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,455
    views
  • 800
    downloads
  • 52
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jeremy Carlos Burns
  2. Bunny Cotleur
  3. Dirk M Walther
  4. Bekim Bajrami
  5. Stephen J Rubino
  6. Ru Wei
  7. Nathalie Franchimont
  8. Susan L Cotman
  9. Richard M Ransohoff
  10. Michael Mingueneau
(2020)
Differential accumulation of storage bodies with aging defines discrete subsets of microglia in the healthy brain
eLife 9:e57495.
https://doi.org/10.7554/eLife.57495

Share this article

https://doi.org/10.7554/eLife.57495

Further reading

    1. Immunology and Inflammation
    2. Medicine
    Joanna C Porter, Jamie Inshaw ... Venizelos Papayannopoulos
    Research Article

    Background:

    Prinflammatory extracellular chromatin from neutrophil extracellular traps (NETs) and other cellular sources is found in COVID-19 patients and may promote pathology. We determined whether pulmonary administration of the endonuclease dornase alfa reduced systemic inflammation by clearing extracellular chromatin.

    Methods:

    Eligible patients were randomized (3:1) to the best available care including dexamethasone (R-BAC) or to BAC with twice-daily nebulized dornase alfa (R-BAC + DA) for seven days or until discharge. A 2:1 ratio of matched contemporary controls (CC-BAC) provided additional comparators. The primary endpoint was the improvement in C-reactive protein (CRP) over time, analyzed using a repeated-measures mixed model, adjusted for baseline factors.

    Results:

    We recruited 39 evaluable participants: 30 randomized to dornase alfa (R-BAC +DA), 9 randomized to BAC (R-BAC), and included 60 CC-BAC participants. Dornase alfa was well tolerated and reduced CRP by 33% compared to the combined BAC groups (T-BAC). Least squares (LS) mean post-dexamethasone CRP fell from 101.9 mg/L to 23.23 mg/L in R-BAC +DA participants versus a 99.5 mg/L to 34.82 mg/L reduction in the T-BAC group at 7 days; p=0.01. The anti-inflammatory effect of dornase alfa was further confirmed with subgroup and sensitivity analyses on randomised participants only, mitigating potential biases associated with the use of CC-BAC participants. Dornase alfa increased live discharge rates by 63% (HR 1.63, 95% CI 1.01–2.61, p=0.03), increased lymphocyte counts (LS mean: 1.08 vs 0.87, p=0.02) and reduced circulating cf-DNA and the coagulopathy marker D-dimer (LS mean: 570.78 vs 1656.96 μg/mL, p=0.004).

    Conclusions:

    Dornase alfa reduces pathogenic inflammation in COVID-19 pneumonia, demonstrating the benefit of cost-effective therapies that target extracellular chromatin.

    Funding:

    LifeArc, Breathing Matters, The Francis Crick Institute (CRUK, Medical Research Council, Wellcome Trust).

    Clinical trial number:

    NCT04359654.

    1. Immunology and Inflammation
    Hee Young Kim, Yeon Jun Kang ... Won-Woo Lee
    Research Article

    Trained immunity is the long-term functional reprogramming of innate immune cells, which results in altered responses toward a secondary challenge. Despite indoxyl sulfate (IS) being a potent stimulus associated with chronic kidney disease (CKD)-related inflammation, its impact on trained immunity has not been explored. Here, we demonstrate that IS induces trained immunity in monocytes via epigenetic and metabolic reprogramming, resulting in augmented cytokine production. Mechanistically, the aryl hydrocarbon receptor (AhR) contributes to IS-trained immunity by enhancing the expression of arachidonic acid (AA) metabolism-related genes such as arachidonate 5-lipoxygenase (ALOX5) and ALOX5 activating protein (ALOX5AP). Inhibition of AhR during IS training suppresses the induction of IS-trained immunity. Monocytes from end-stage renal disease (ESRD) patients have increased ALOX5 expression and after 6 days training, they exhibit enhanced TNF-α and IL-6 production to lipopolysaccharide (LPS). Furthermore, healthy control-derived monocytes trained with uremic sera from ESRD patients exhibit increased production of TNF-α and IL-6. Consistently, IS-trained mice and their splenic myeloid cells had increased production of TNF-α after in vivo and ex vivo LPS stimulation compared to that of control mice. These results provide insight into the role of IS in the induction of trained immunity, which is critical during inflammatory immune responses in CKD patients.